Protein Degradation Therapy Market Report 2026

The protein degradation therapy market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to advancements in molecular biology research, expansion of targeted cancer therapies, increased understanding of protein dysfunction in diseases, early-stage clinical successes, growing venture capital funding in biotech.

The protein degradation therapy market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing demand for novel cancer therapies, rising investments in precision oncology, expansion of protein degradation platforms, growing clinical trial activity, increasing regulatory support for innovative therapeutics. Major trends in the forecast period include increasing development of targeted protein degraders, rising focus on oncology applications, growing investment in protac-based therapies, expansion of clinical pipeline candidates, enhanced collaboration between pharma and biotech firms.

The increasing burden of cancer is expected to drive the growth of the protein degradation therapy market in the future. Cancer encompasses a variety of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The rising cancer rates are largely due to factors such as an aging population, lifestyle choices like smoking, poor diet, lack of physical activity, and increasing obesity rates, all of which have heightened the risk of different cancers. Protein degradation therapy is vital for treating cancer because it targets and eliminates specific proteins that promote cancer growth and survival, potentially overcoming resistance to conventional treatments. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, predicted that over 35 million new cancer cases are expected by 2050, marking a 77% increase from the estimated 20 million cases in 2022. Furthermore, high human development index (HDI) countries are forecasted to experience the largest rise in absolute numbers, with an additional 4.8 million new cases in 2050 compared to 2022 estimates. Therefore, the growing cancer burden is fueling the expansion of the protein degradation therapy market.

Leading companies in the protein degradation therapy market are forming strategic partnerships to develop innovative therapies, leverage complementary expertise, share resources, and accelerate the discovery and development of new drug candidates targeting disease-causing proteins. These partnerships enable companies to use each other's strengths and resources to gain mutual benefits and achieve shared success. For example, in February 2024, Arvinas, a U.S.-based biotechnology company, launched its first oral PROTAC degrader (ARV-102), designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule offers oral bioavailability, brain penetration, and high specificity for LRRK2. This innovation strengthens the company's pipeline by targeting previously undruggable targets, although challenges remain around long-term safety, manufacturing complexity, and optimizing pharmacokinetics due to the larger molecular structure.

In June 2024, Genexine, a South Korea-based biopharmaceutical company, merged with EPD Biotherapeutics for an undisclosed amount. This merger enabled Genexine to acquire key talent and cutting-edge technology, positioning it to lead the global market. Additionally, the integration of EPD Bio’s bioPROTAC technology with Genexine’s clinical and CMC development capabilities is expected to accelerate the development of groundbreaking new drugs. EPD Biotherapeutics is a South Korea-based developer of the protein degradation platform known as EPDeg.

Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc.

North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the protein degradation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the protein degradation therapy market by increasing costs of imported research reagents, laboratory equipment, specialized chemical compounds, and bioprocessing tools used in drug discovery and clinical development. Biotechnology hubs in North America and Europe are most affected due to reliance on imported research materials, while Asia-Pacific faces cost pressure on compound synthesis and testing. These tariffs are raising R&D expenditures and extending development timelines. However, they are also encouraging localized research infrastructure, domestic reagent production, and regional partnerships in advanced therapeutic development.

The protein degradation therapy market research report is one of a series of new reports that provides protein degradation therapy market statistics, including protein degradation therapy industry global market size, regional shares, competitors with a protein degradation therapy market share, detailed protein degradation therapy market segments, market trends and opportunities, and any further data you may need to thrive in the protein degradation therapy industry. This protein degradation therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Protein degradation therapy is a therapeutic approach that focuses on the selective degradation of specific proteins within cells. This method involves using small molecules, peptides, or other agents to promote the destruction of proteins that are dysfunctional or contribute to disease. The aim is to reduce or eliminate harmful proteins associated with various conditions, such as cancer, neurodegenerative diseases, and autoimmune disorders.

Key therapies in protein degradation include bavdegalutamide (ARV-110), vepdegestrant (ARV-471), and others. Bavdegalutamide, also known as ARV-110, is a novel therapy developed to target and degrade androgen receptors in prostate cancer cells. This therapy is used in the treatment of oncology, neurodegenerative diseases, infectious diseases, and other conditions by various end-users, including pharmaceutical companies, biotechnology companies, and academic and research institutes.

The protein degradation therapy market consists of revenues earned by entities by providing services such as drug discovery and development, target validation, preclinical and clinical testing and targeted protein degradation screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The protein degradation therapy market also includes sales of degraders, E3 ligase ligands, degron tags, biochemical assay kits and cellular assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.